BioSpace News Archive

Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing potential immune correlates of protection to facilitate vaccine approval under the Food and Drug Administration (FDA) Animal Rule.

Revenues: $2.53 billion

Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018

Innovative Angiography System Delivers Industry-Leading Dose Management Tools as a Part of Slidell’s New Patient-Focused Cath Lab

If you want a free Stock Review on GWPH, ABBV, AZN, and BMY sign up now at https://stocktraderreport.com/registration.

Q2 2018 GAAP Loss Per Share of $1.39; Non-GAAP Performance Net Income Per Share of $4.42

MAXIMUS will issue a press release with its financial results for the three and nine months ended June 30, 2018, at 6:30 a.m. ET on Thursday, August 9, 2018, and will host a conference call the same day at 9:00 a.m. ET.

Alexion Pharmaceuticals, Inc. today announced financial results for the second quarter of 2018.

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA®, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

BD® AbSeq Assay Enables Deeper Understanding of Role Individual Cells Play in the Immune System